ERBB2 and inflammatory breast carcinoma: In a retrospective review of a prospectively maintained single-institution database, 453 patients with nonmetastatic IBC were examined to evaluate the frequency and factors associated with pathologic node-negativity (ypN0).42 Overall, 34% (156 of 453) were ypN0 after NST; ycN0 status and hormone receptor–negative/ERBB2-positive subtype were associated with nodal pathologic complete response (ypN0).